ATAI Life Sciences is trading 5.7% up at $5.25 following a price-target increase from Canaccord Genuity and continued optimism surrounding its depression-focused clinical pipeline.
- Canaccord Genuity maintained its Buy rating and raised its price target to $17, highlighting the potential for strong returns despite high volatility in the name.
- The stock continues to benefit from a powerful year-long rally driven by positive clinical data and a series of bullish analyst actions.